[
  {
    "id": "1",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Andorra",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "less_than_3_months ",
    "uptake": "65.70%"
  },
  {
    "id": "2",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Andorra",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "3_to_6_months ",
    "uptake": "51.10%"
  },
  {
    "id": "3",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Andorra",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "6_to_12_months ",
    "uptake": "54.80%"
  },
  {
    "id": "4",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Andorra",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "comorbidity_no",
    "uptake": "54.20%"
  },
  {
    "id": "5",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Andorra",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "preterm_birth_yes",
    "uptake": "79.50%"
  },
  {
    "id": "6",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Andorra",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "cardiac_comorbidity",
    "uptake": "60.00%"
  },
  {
    "id": "7",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Andorra",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "lung_comorbidity",
    "uptake": "100.00%"
  },
  {
    "id": "8",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Andorra",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "neuro_comorbidity",
    "uptake": "66.70%"
  },
  {
    "id": "9",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Andorra",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "other_comorbidity",
    "uptake": "20.00%"
  },
  {
    "id": "10",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Andorra",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "sex",
    "subFilterValue": "male",
    "uptake": "63.70%"
  },
  {
    "id": "11",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Andorra",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "sex",
    "subFilterValue": "female",
    "uptake": "54.40%"
  },
  {
    "id": "12",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Andorra",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "60.20%"
  },
  {
    "id": "13",
    "study": "Carbajal et al. (2024)",
    "healthStatus": "other",
    "country": "France",
    "city": "Paris",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "emergency",
    "subFilterKey": "age_group",
    "subFilterValue": "less_than_3_months ",
    "uptake": "58.20%"
  },
  {
    "id": "14",
    "study": "Carbajal et al. (2024)",
    "healthStatus": "other",
    "country": "France",
    "city": "Paris",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "emergency",
    "subFilterKey": "age_group",
    "subFilterValue": "3_to_6_months ",
    "uptake": "37.60%"
  },
  {
    "id": "15",
    "study": "Carbajal et al. (2024)",
    "healthStatus": "other",
    "country": "France",
    "city": "Paris",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "emergency",
    "subFilterKey": "age_group",
    "subFilterValue": "6_to_12_months ",
    "uptake": "18.00%"
  },
  {
    "id": "16",
    "study": "Carbajal et al. (2024)",
    "healthStatus": "other",
    "country": "France",
    "city": "Paris",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "emergency",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "36.50%"
  },
  {
    "id": "17",
    "study": "Carbajal et al. (2024)",
    "healthStatus": "rsv_ARI",
    "country": "France",
    "city": "Paris",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "emergency",
    "subFilterKey": "age_group",
    "subFilterValue": "less_than_3_months ",
    "uptake": "23.00%"
  },
  {
    "id": "18",
    "study": "Carbajal et al. (2024)",
    "healthStatus": "rsv_ARI",
    "country": "France",
    "city": "Paris",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "emergency",
    "subFilterKey": "age_group",
    "subFilterValue": "3_to_6_months ",
    "uptake": "2.90%"
  },
  {
    "id": "19",
    "study": "Carbajal et al. (2024)",
    "healthStatus": "rsv_ARI",
    "country": "France",
    "city": "Paris",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "emergency",
    "subFilterKey": "age_group",
    "subFilterValue": "6_to_12_months ",
    "uptake": "0.00%"
  },
  {
    "id": "20",
    "study": "Carbajal et al. (2024)",
    "healthStatus": "rsv_ARI",
    "country": "France",
    "city": "Paris",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "emergency",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "11.00%"
  },
  {
    "id": "21",
    "study": "Carbajal et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "France",
    "city": "Paris",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "less_than_3_months ",
    "uptake": "37.60%"
  },
  {
    "id": "22",
    "study": "Carbajal et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "France",
    "city": "Paris",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "3_to_6_months ",
    "uptake": "12.40%"
  },
  {
    "id": "23",
    "study": "Carbajal et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "France",
    "city": "Paris",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "6_to_12_months ",
    "uptake": "13.40%"
  },
  {
    "id": "24",
    "study": "Carbajal et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "France",
    "city": "Paris",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "23.60%"
  },
  {
    "id": "25",
    "study": "Carbajal et al. (2024)",
    "healthStatus": "rsv_ARI",
    "country": "France",
    "city": "Paris",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "less_than_3_months ",
    "uptake": "23.00%"
  },
  {
    "id": "26",
    "study": "Carbajal et al. (2024)",
    "healthStatus": "rsv_ARI",
    "country": "France",
    "city": "Paris",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "3_to_6_months ",
    "uptake": "3.00%"
  },
  {
    "id": "27",
    "study": "Carbajal et al. (2024)",
    "healthStatus": "rsv_ARI",
    "country": "France",
    "city": "Paris",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "6_to_12_months ",
    "uptake": "0.00%"
  },
  {
    "id": "28",
    "study": "Carbajal et al. (2024)",
    "healthStatus": "rsv_ARI",
    "country": "France",
    "city": "Paris",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "11.50%"
  },
  {
    "id": "29",
    "study": "Consolati et al. (2024)",
    "healthStatus": "healthy",
    "country": "Italy",
    "city": "Valle d' Aosta",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "68.70%"
  },
  {
    "id": "30",
    "study": "Consolati et al. (2024)",
    "healthStatus": "healthy",
    "country": "Italy",
    "city": "Valle d' Aosta",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "enrolment",
    "subFilterValue": "season",
    "uptake": "86.50%"
  },
  {
    "id": "31",
    "study": "Consolati et al. (2024)",
    "healthStatus": "healthy",
    "country": "Italy",
    "city": "Valle d' Aosta",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "enrolment",
    "subFilterValue": "catch",
    "uptake": "65.20%"
  },
  {
    "id": "32",
    "study": "Ernst et al. (2024)",
    "healthStatus": "healthy",
    "country": "Luxembourg",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "enrolment",
    "subFilterValue": "catch",
    "uptake": "83.80%"
  },
  {
    "id": "33",
    "study": "Martinon-Torres et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_24_months ",
    "setting": "community",
    "subFilterKey": "enrolment",
    "subFilterValue": "risk",
    "uptake": "97.50%"
  },
  {
    "id": "34",
    "study": "Martinon-Torres et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "81.40%"
  },
  {
    "id": "35",
    "study": "Lopez-Lacort et al. (2025)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "primary",
    "subFilterKey": "age_group",
    "subFilterValue": "less_than_3_months ",
    "uptake": "92.50%"
  },
  {
    "id": "36",
    "study": "Lopez-Lacort et al. (2025)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "primary",
    "subFilterKey": "age_group",
    "subFilterValue": "3_to_6_months ",
    "uptake": "86.00%"
  },
  {
    "id": "37",
    "study": "Lopez-Lacort et al. (2025)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Murcia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "primary",
    "subFilterKey": "age_group",
    "subFilterValue": "less_than_3_months ",
    "uptake": "92.50%"
  },
  {
    "id": "38",
    "study": "Lopez-Lacort et al. (2025)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Murcia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "primary",
    "subFilterKey": "age_group",
    "subFilterValue": "3_to_6_months ",
    "uptake": "86.00%"
  },
  {
    "id": "39",
    "study": "Lopez-Lacort et al. (2025)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "primary",
    "subFilterKey": "sex",
    "subFilterValue": "male",
    "uptake": "90.20%"
  },
  {
    "id": "40",
    "study": "Lopez-Lacort et al. (2025)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "primary",
    "subFilterKey": "sex",
    "subFilterValue": "female",
    "uptake": "84.50%"
  },
  {
    "id": "41",
    "study": "Lopez-Lacort et al. (2025)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Murcia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "primary",
    "subFilterKey": "sex",
    "subFilterValue": "male",
    "uptake": "90.20%"
  },
  {
    "id": "42",
    "study": "Lopez-Lacort et al. (2025)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Murcia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "primary",
    "subFilterKey": "sex",
    "subFilterValue": "female",
    "uptake": "84.50%"
  },
  {
    "id": "43",
    "study": "Lopez-Lacort et al. (2025)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "primary",
    "subFilterKey": "comorbidity",
    "subFilterValue": "preterm_birth_yes",
    "uptake": "88.90%"
  },
  {
    "id": "44",
    "study": "Lopez-Lacort et al. (2025)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "primary",
    "subFilterKey": "daycare_yes",
    "subFilterValue": "daycare_yes",
    "uptake": "83.30%"
  },
  {
    "id": "45",
    "study": "Lopez-Lacort et al. (2025)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "primary",
    "subFilterKey": "enrolment",
    "subFilterValue": "season",
    "uptake": "90.60%"
  },
  {
    "id": "46",
    "study": "Lopez-Lacort et al. (2025)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "primary",
    "subFilterKey": "enrolment",
    "subFilterValue": "catch",
    "uptake": "87.50%"
  },
  {
    "id": "47",
    "study": "Lopez-Lacort et al. (2025)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "primary",
    "subFilterKey": "siblings_yes",
    "subFilterValue": "siblings_yes",
    "uptake": "88.60%"
  },
  {
    "id": "48",
    "study": "Lopez-Lacort et al. (2025)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Murcia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "primary",
    "subFilterKey": "comorbidity",
    "subFilterValue": "preterm_birth_yes",
    "uptake": "88.90%"
  },
  {
    "id": "49",
    "study": "Lopez-Lacort et al. (2025)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Murcia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "primary",
    "subFilterKey": "daycare_yes",
    "subFilterValue": "daycare_yes",
    "uptake": "83.30%"
  },
  {
    "id": "50",
    "study": "Lopez-Lacort et al. (2025)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Murcia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "primary",
    "subFilterKey": "enrolment",
    "subFilterValue": "season",
    "uptake": "90.60%"
  },
  {
    "id": "51",
    "study": "Lopez-Lacort et al. (2025)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Murcia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "primary",
    "subFilterKey": "enrolment",
    "subFilterValue": "catch",
    "uptake": "87.50%"
  },
  {
    "id": "52",
    "study": "Lopez-Lacort et al. (2025)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Murcia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "primary",
    "subFilterKey": "siblings_yes",
    "subFilterValue": "siblings_yes",
    "uptake": "88.60%"
  },
  {
    "id": "53",
    "study": "Lopez-Lacort et al. (2025)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "primary",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "88.10%"
  },
  {
    "id": "54",
    "study": "Lopez-Lacort et al. (2025)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Murcia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "primary",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "88.10%"
  },
  {
    "id": "55",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "age_group",
    "subFilterValue": "less_than_3_months ",
    "uptake": "95.00%"
  },
  {
    "id": "56",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "age_group",
    "subFilterValue": "3_to_6_months ",
    "uptake": "90.00%"
  },
  {
    "id": "57",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "age_group",
    "subFilterValue": "6_to_12_months ",
    "uptake": "88.30%"
  },
  {
    "id": "58",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "preterm_birth_yes",
    "uptake": "93.90%"
  },
  {
    "id": "59",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "preterm_birth_under35",
    "uptake": "95.60%"
  },
  {
    "id": "60",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "preterm_birth_under29",
    "uptake": "100.00%"
  },
  {
    "id": "61",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "cardiac_comorbidity",
    "uptake": "98.50%"
  },
  {
    "id": "62",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "lung_comorbidity",
    "uptake": "97.40%"
  },
  {
    "id": "63",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "immunosuppression",
    "uptake": "90.00%"
  },
  {
    "id": "64",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "metabolic_comorbidity",
    "uptake": "92.90%"
  },
  {
    "id": "65",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "neuro_comorbidity",
    "uptake": "100.00%"
  },
  {
    "id": "66",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "lung_comorbidity",
    "uptake": "100.00%"
  },
  {
    "id": "67",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "genetic_comorbidity",
    "uptake": "90.00%"
  },
  {
    "id": "68",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "genetic_comorbidity",
    "uptake": "100.00%"
  },
  {
    "id": "69",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "palliative_care",
    "uptake": "100.00%"
  },
  {
    "id": "70",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "enrolment",
    "subFilterValue": "season",
    "uptake": "95.40%"
  },
  {
    "id": "71",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "enrolment",
    "subFilterValue": "catch",
    "uptake": "89.90%"
  },
  {
    "id": "72",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "enrolment",
    "subFilterValue": "risk",
    "uptake": "96.70%"
  },
  {
    "id": "73",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "healthy_programme",
    "subFilterValue": "healthy_at_least_one",
    "uptake": "92.50%"
  },
  {
    "id": "74",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "healthy_programme",
    "subFilterValue": "healthy_none",
    "uptake": "81.70%"
  },
  {
    "id": "75",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "region",
    "subFilterValue": "north",
    "uptake": "92.00%"
  },
  {
    "id": "76",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "region",
    "subFilterValue": "south",
    "uptake": "91.30%"
  },
  {
    "id": "77",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "birth_type",
    "subFilterValue": "single",
    "uptake": "79.90%"
  },
  {
    "id": "78",
    "study": "Ares-Gomez et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "birth_type",
    "subFilterValue": "multiple",
    "uptake": "86.60%"
  },
  {
    "id": "79",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "preterm_birth_under29",
    "uptake": "78.60%"
  },
  {
    "id": "80",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "preterm_birth_under35",
    "uptake": "86.60%"
  },
  {
    "id": "81",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "preterm_birth_yes",
    "uptake": "81.90%"
  },
  {
    "id": "82",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "preterm_birth_no",
    "uptake": "80.00%"
  },
  {
    "id": "83",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "preterm_birth_no",
    "uptake": "53.30%"
  },
  {
    "id": "84",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "comorbidity_no",
    "uptake": "79.80%"
  },
  {
    "id": "85",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "comorbidity_yes",
    "uptake": "83.60%"
  },
  {
    "id": "86",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "preterm_birth_under35",
    "uptake": "84.70%"
  },
  {
    "id": "87",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "lung_comorbidity",
    "uptake": "78.80%"
  },
  {
    "id": "88",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "cardiac_comorbidity",
    "uptake": "80.00%"
  },
  {
    "id": "89",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "immunosuppression",
    "uptake": "81.30%"
  },
  {
    "id": "90",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "metabolic_comorbidity",
    "uptake": "84.10%"
  },
  {
    "id": "91",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "neuro_comorbidity",
    "uptake": "79.50%"
  },
  {
    "id": "92",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "palliative_care",
    "uptake": "100.00%"
  },
  {
    "id": "93",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "income",
    "subFilterValue": "up_to_10 ",
    "uptake": "64.70%"
  },
  {
    "id": "94",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "income",
    "subFilterValue": "11_to_30 ",
    "uptake": "72.10%"
  },
  {
    "id": "95",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "income",
    "subFilterValue": "31_to_50 ",
    "uptake": "78.60%"
  },
  {
    "id": "96",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "income",
    "subFilterValue": "51_to_70 ",
    "uptake": "85.60%"
  },
  {
    "id": "97",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "income",
    "subFilterValue": "71_to_90 ",
    "uptake": "89.30%"
  },
  {
    "id": "98",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "income",
    "subFilterValue": "91_to_100 ",
    "uptake": "90.20%"
  },
  {
    "id": "99",
    "study": "Coma et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "sex",
    "subFilterValue": "female",
    "uptake": "92.00%"
  },
  {
    "id": "100",
    "study": "Coma et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "sex",
    "subFilterValue": "male",
    "uptake": "91.40%"
  },
  {
    "id": "101",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "sex",
    "subFilterValue": "female",
    "uptake": "79.70%"
  },
  {
    "id": "102",
    "study": "Coma et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Catalonia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "nationality",
    "subFilterValue": "spanish",
    "uptake": "87.80%"
  },
  {
    "id": "103",
    "study": "Coma et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Catalonia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "residential_area",
    "subFilterValue": "rural",
    "uptake": "86.10%"
  },
  {
    "id": "104",
    "study": "Barbas del Buey et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "community",
    "subFilterKey": "sex",
    "subFilterValue": "male",
    "uptake": "80.50%"
  },
  {
    "id": "105",
    "study": "Coma et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Catalonia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "sex",
    "subFilterValue": "male",
    "uptake": "87.30%"
  },
  {
    "id": "106",
    "study": "Estrella-Porter et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "sex",
    "subFilterValue": "male",
    "uptake": "88.30%"
  },
  {
    "id": "107",
    "study": "Estrella-Porter et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "sex",
    "subFilterValue": "female",
    "uptake": "88.80%"
  },
  {
    "id": "108",
    "study": "Estrella-Porter et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "birth_weight",
    "subFilterValue": "underweight_no",
    "uptake": "88.60%"
  },
  {
    "id": "109",
    "study": "Estrella-Porter et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "birth_weight",
    "subFilterValue": "underweight_yes",
    "uptake": "75.00%"
  },
  {
    "id": "110",
    "study": "Estrella-Porter et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "term_birth",
    "uptake": "88.50%"
  },
  {
    "id": "111",
    "study": "Estrella-Porter et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "preterm_birth",
    "uptake": "88.40%"
  },
  {
    "id": "112",
    "study": "Estrella-Porter et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "enrolment",
    "subFilterValue": "catch",
    "uptake": "86.50%"
  },
  {
    "id": "113",
    "study": "Estrella-Porter et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "enrolment",
    "subFilterValue": "season",
    "uptake": "92.10%"
  },
  {
    "id": "114",
    "study": "Estrella-Porter et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "maternal",
    "subFilterValue": "maternal_feed_yes ",
    "uptake": "88.30%"
  },
  {
    "id": "115",
    "study": "Estrella-Porter et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "maternal",
    "subFilterValue": "maternal_feed_no ",
    "uptake": "89.00%"
  },
  {
    "id": "116",
    "study": "Estrella-Porter et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "maternity_service",
    "subFilterValue": "private",
    "uptake": "82.60%"
  },
  {
    "id": "117",
    "study": "Estrella-Porter et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "maternity_service",
    "subFilterValue": "non_private",
    "uptake": "90.20%"
  },
  {
    "id": "118",
    "study": "Estrella-Porter et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "nationality",
    "subFilterValue": "spanish",
    "uptake": "91.70%"
  },
  {
    "id": "119",
    "study": "Estrella-Porter et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "nationality",
    "subFilterValue": "non_spanish",
    "uptake": "83.90%"
  },
  {
    "id": "120",
    "study": "Estrella-Porter et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "community",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "88.50%"
  },
  {
    "id": "121",
    "study": "Alejandre et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Catalonia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "picu",
    "subFilterKey": "comorbidity",
    "subFilterValue": "comorbidity_no",
    "uptake": "58.80%"
  },
  {
    "id": "122",
    "study": "Alejandre et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Catalonia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "picu",
    "subFilterKey": "comorbidity",
    "subFilterValue": "preterm_birth_yes",
    "uptake": "84.60%"
  },
  {
    "id": "123",
    "study": "Alejandre et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Catalonia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "picu",
    "subFilterKey": "comorbidity",
    "subFilterValue": "cardiac_comorbidity",
    "uptake": "100.00%"
  },
  {
    "id": "124",
    "study": "Alejandre et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Catalonia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "picu",
    "subFilterKey": "comorbidity",
    "subFilterValue": "neuro_comorbidity",
    "uptake": "50.00%"
  },
  {
    "id": "125",
    "study": "Alejandre et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Catalonia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "picu",
    "subFilterKey": "sex",
    "subFilterValue": "male",
    "uptake": "73.30%"
  },
  {
    "id": "126",
    "study": "Alejandre et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Catalonia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "picu",
    "subFilterKey": "sex",
    "subFilterValue": "female",
    "uptake": "59.10%"
  },
  {
    "id": "127",
    "study": "Alejandre et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "Catalonia",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "picu",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "67.30%"
  },
  {
    "id": "128",
    "study": "Molina Gutierrez et al. (2024)",
    "healthStatus": "rsv_ARI",
    "country": "Spain",
    "city": "Madrid",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "emergency",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "36.50%"
  },
  {
    "id": "129",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "less_than_3_months ",
    "uptake": "65.70%"
  },
  {
    "id": "130",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "3_to_6_months ",
    "uptake": "51.10%"
  },
  {
    "id": "131",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "6_to_12_months ",
    "uptake": "54.80%"
  },
  {
    "id": "132",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "comorbidity_no",
    "uptake": "54.20%"
  },
  {
    "id": "133",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "preterm_birth_yes",
    "uptake": "79.50%"
  },
  {
    "id": "134",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "cardiac_comorbidity",
    "uptake": "60.00%"
  },
  {
    "id": "135",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "lung_comorbidity",
    "uptake": "100.00%"
  },
  {
    "id": "136",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "neuro_comorbidity",
    "uptake": "66.70%"
  },
  {
    "id": "137",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "other_comorbidity",
    "uptake": "20.00%"
  },
  {
    "id": "138",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "sex",
    "subFilterValue": "male",
    "uptake": "63.70%"
  },
  {
    "id": "139",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "sex",
    "subFilterValue": "female",
    "uptake": "54.40%"
  },
  {
    "id": "140",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "60.20%"
  },
  {
    "id": "141",
    "study": "Aguera et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "Spain",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_6_months",
    "setting": "hospital",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "54.40%"
  },
  {
    "id": "142",
    "study": "Lopez-Lacort et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Valencia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "90.00%"
  },
  {
    "id": "143",
    "study": "Lopez-Lacort et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Murcia",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "90.00%"
  },
  {
    "id": "144",
    "study": "Lopez-Lacort et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Valladolid",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "90.00%"
  },
  {
    "id": "145",
    "study": "Ezpeleta et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Navarre",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "sex",
    "subFilterValue": "male",
    "uptake": "92.20%"
  },
  {
    "id": "146",
    "study": "Ezpeleta et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Navarre",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "sex",
    "subFilterValue": "female",
    "uptake": "91.70%"
  },
  {
    "id": "147",
    "study": "Ezpeleta et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Navarre",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "92.00%"
  },
  {
    "id": "148",
    "study": "Martinon-Torres et al. (2024)",
    "healthStatus": "healthy",
    "country": "Spain",
    "city": "Galicia",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "92.60%"
  },
  {
    "id": "149",
    "study": "Lefferts et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Alaska",
    "intervention": "nirsevimab",
    "population": "under_24_months ",
    "setting": "hospital",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "47.50%"
  },
  {
    "id": "150",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "less_than_3_months ",
    "uptake": "9.00%"
  },
  {
    "id": "151",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "less_than_3_months ",
    "uptake": "8.40%"
  },
  {
    "id": "152",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "3_to_6_months ",
    "uptake": "6.90%"
  },
  {
    "id": "153",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "3_to_6_months ",
    "uptake": "5.00%"
  },
  {
    "id": "154",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "6_to_12_months ",
    "uptake": "9.40%"
  },
  {
    "id": "155",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "6_to_12_months ",
    "uptake": "26.10%"
  },
  {
    "id": "156",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "6_to_12_months ",
    "uptake": "33.30%"
  },
  {
    "id": "157",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "sex",
    "subFilterValue": "female",
    "uptake": "9.60%"
  },
  {
    "id": "158",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "sex",
    "subFilterValue": "male",
    "uptake": "7.60%"
  },
  {
    "id": "159",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "preterm_birth_yes",
    "uptake": "10.30%"
  },
  {
    "id": "160",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "preterm_birth_no",
    "uptake": "8.00%"
  },
  {
    "id": "161",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "comorbidity_yes",
    "uptake": "46.20%"
  },
  {
    "id": "162",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "comorbidity_no",
    "uptake": "6.20%"
  },
  {
    "id": "163",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "alaska_native",
    "uptake": "0.00%"
  },
  {
    "id": "164",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "asian",
    "uptake": "6.40%"
  },
  {
    "id": "165",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "black",
    "uptake": "9.00%"
  },
  {
    "id": "166",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "hawaiian_native",
    "uptake": "10.20%"
  },
  {
    "id": "167",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "white",
    "uptake": "16.70%"
  },
  {
    "id": "168",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "hispanic",
    "uptake": "0.00%"
  },
  {
    "id": "169",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "multiple_other",
    "uptake": "6.40%"
  },
  {
    "id": "170",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "unknown",
    "uptake": "10.50%"
  },
  {
    "id": "171",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "insurance",
    "subFilterValue": "public",
    "uptake": "9.60%"
  },
  {
    "id": "172",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "insurance",
    "subFilterValue": "private",
    "uptake": "7.30%"
  },
  {
    "id": "173",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "insurance",
    "subFilterValue": "public_and_private ",
    "uptake": "25.00%"
  },
  {
    "id": "174",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "insurance",
    "subFilterValue": "no_insurance",
    "uptake": "7.80%"
  },
  {
    "id": "175",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "insurance",
    "subFilterValue": "unknown_insurance",
    "uptake": "0.00%"
  },
  {
    "id": "176",
    "study": "Moline et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_12_months",
    "setting": "hospital",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "8.40%"
  },
  {
    "id": "177",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "ethnicity",
    "subFilterValue": "black",
    "uptake": "51.10%"
  },
  {
    "id": "178",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "ethnicity",
    "subFilterValue": "white",
    "uptake": "44.20%"
  },
  {
    "id": "179",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "ethnicity",
    "subFilterValue": "hispanic",
    "uptake": "43.90%"
  },
  {
    "id": "180",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "ethnicity",
    "subFilterValue": "multiple_other",
    "uptake": "38.50%"
  },
  {
    "id": "181",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "insurance",
    "subFilterValue": "private",
    "uptake": "43.10%"
  },
  {
    "id": "182",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "insurance",
    "subFilterValue": "public",
    "uptake": "46.90%"
  },
  {
    "id": "183",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "insurance",
    "subFilterValue": "no_insurance",
    "uptake": "0.00%"
  },
  {
    "id": "184",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "maternal_age",
    "subFilterValue": "maternal_age_35_to_49 ",
    "uptake": "48.40%"
  },
  {
    "id": "185",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "maternal_age",
    "subFilterValue": "maternal_age_25_to_34 ",
    "uptake": "42.50%"
  },
  {
    "id": "186",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "maternal_age",
    "subFilterValue": "maternal_age_18_to_24 ",
    "uptake": "46.50%"
  },
  {
    "id": "187",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "education",
    "subFilterValue": "maternal_edu_highest ",
    "uptake": "37.20%"
  },
  {
    "id": "188",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "education",
    "subFilterValue": "maternal_edu_college_degree ",
    "uptake": "46.20%"
  },
  {
    "id": "189",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "education",
    "subFilterValue": "maternal_edu_college ",
    "uptake": "45.30%"
  },
  {
    "id": "190",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "education",
    "subFilterValue": "maternal_edu_high_school ",
    "uptake": "45.00%"
  },
  {
    "id": "191",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "employment",
    "subFilterValue": "maternal_employ_yes ",
    "uptake": "48.50%"
  },
  {
    "id": "192",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "employment",
    "subFilterValue": "maternal_employ_no ",
    "uptake": "38.70%"
  },
  {
    "id": "193",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "poverty_status",
    "subFilterValue": "above_poverty",
    "uptake": "44.50%"
  },
  {
    "id": "194",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "poverty_status",
    "subFilterValue": "below_poverty",
    "uptake": "44.70%"
  },
  {
    "id": "195",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "provider",
    "subFilterValue": "provider_yes",
    "uptake": "58.70%"
  },
  {
    "id": "196",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "provider",
    "subFilterValue": "provider_no ",
    "uptake": "28.30%"
  },
  {
    "id": "197",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "region",
    "subFilterValue": "northeast",
    "uptake": "44.00%"
  },
  {
    "id": "198",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "region",
    "subFilterValue": "midwest",
    "uptake": "48.70%"
  },
  {
    "id": "199",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "region",
    "subFilterValue": "south",
    "uptake": "47.40%"
  },
  {
    "id": "200",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "region",
    "subFilterValue": "west",
    "uptake": "36.60%"
  },
  {
    "id": "201",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "residential_area",
    "subFilterValue": "urban",
    "uptake": "44.70%"
  },
  {
    "id": "202",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "residential_area",
    "subFilterValue": "rural",
    "uptake": "43.90%"
  },
  {
    "id": "203",
    "study": "Razzaghi et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "nirsevimab",
    "population": "under_3_months ",
    "setting": "community",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "44.60%"
  },
  {
    "id": "204",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "sex",
    "subFilterValue": "male",
    "uptake": "69.60%"
  },
  {
    "id": "205",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "sex",
    "subFilterValue": "female",
    "uptake": "73.30%"
  },
  {
    "id": "206",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "cardiac_comorbidity",
    "uptake": "88.90%"
  },
  {
    "id": "207",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "comorbidity",
    "subFilterValue": "lung_comorbidity",
    "uptake": "77.80%"
  },
  {
    "id": "208",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "discharge_age",
    "subFilterValue": "less_than_3_days ",
    "uptake": "69.30%"
  },
  {
    "id": "209",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "discharge_age",
    "subFilterValue": "3_or_more_days ",
    "uptake": "76.40%"
  },
  {
    "id": "210",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "discharge_unit",
    "subFilterValue": "newborn_nursery ",
    "uptake": "69.10%"
  },
  {
    "id": "211",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "discharge_unit",
    "subFilterValue": "intermediate_nursery ",
    "uptake": "84.40%"
  },
  {
    "id": "212",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "discharge_unit",
    "subFilterValue": "neonatal_icu ",
    "uptake": "68.80%"
  },
  {
    "id": "213",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "ethnicity",
    "subFilterValue": "hispanic",
    "uptake": "75.30%"
  },
  {
    "id": "214",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "ethnicity",
    "subFilterValue": "asian",
    "uptake": "74.50%"
  },
  {
    "id": "215",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "ethnicity",
    "subFilterValue": "white",
    "uptake": "66.30%"
  },
  {
    "id": "216",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "ethnicity",
    "subFilterValue": "multiple_other",
    "uptake": "56.50%"
  },
  {
    "id": "217",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "ethnicity",
    "subFilterValue": "multiple_other",
    "uptake": "73.80%"
  },
  {
    "id": "218",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "ethnicity",
    "subFilterValue": "unknown",
    "uptake": "65.90%"
  },
  {
    "id": "219",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "hep_b_vaccine_yes",
    "subFilterValue": "hep_b_vaccine_yes",
    "uptake": "75.90%"
  },
  {
    "id": "220",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "insurance",
    "subFilterValue": "private",
    "uptake": "71.80%"
  },
  {
    "id": "221",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "insurance",
    "subFilterValue": "public",
    "uptake": "71.50%"
  },
  {
    "id": "222",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "insurance",
    "subFilterValue": "unknown_insurance",
    "uptake": "33.30%"
  },
  {
    "id": "223",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "language",
    "subFilterValue": "english",
    "uptake": "68.30%"
  },
  {
    "id": "224",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "language",
    "subFilterValue": "spanish",
    "uptake": "80.40%"
  },
  {
    "id": "225",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "language",
    "subFilterValue": "other",
    "uptake": "70.00%"
  },
  {
    "id": "226",
    "study": "Puckett et al. (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "California",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "community",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "70.80%"
  },
  {
    "id": "227",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Connecticut",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "sex",
    "subFilterValue": "male",
    "uptake": "10.80%"
  },
  {
    "id": "228",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Connecticut",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "sex",
    "subFilterValue": "female",
    "uptake": "10.50%"
  },
  {
    "id": "229",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "New York",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "sex",
    "subFilterValue": "male",
    "uptake": "10.80%"
  },
  {
    "id": "230",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "New York",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "sex",
    "subFilterValue": "female",
    "uptake": "10.50%"
  },
  {
    "id": "231",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Rhode Island",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "sex",
    "subFilterValue": "male",
    "uptake": "10.80%"
  },
  {
    "id": "232",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Rhode Island",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "sex",
    "subFilterValue": "female",
    "uptake": "10.50%"
  },
  {
    "id": "233",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Connecticut",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "preterm_birth_yes",
    "uptake": "21.50%"
  },
  {
    "id": "234",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Connecticut",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "lung_comorbidity",
    "uptake": "12.20%"
  },
  {
    "id": "235",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Connecticut",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "cardiac_comorbidity",
    "uptake": "21.70%"
  },
  {
    "id": "236",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Connecticut",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "anemia",
    "uptake": "11.70%"
  },
  {
    "id": "237",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Connecticut",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "comorbidity_yes",
    "uptake": "16.40%"
  },
  {
    "id": "238",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Connecticut",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "hispanic",
    "uptake": "10.40%"
  },
  {
    "id": "239",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Connecticut",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "white",
    "uptake": "8.30%"
  },
  {
    "id": "240",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Connecticut",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "black",
    "uptake": "16.10%"
  },
  {
    "id": "241",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Connecticut",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "multiple_other",
    "uptake": "14.90%"
  },
  {
    "id": "242",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Connecticut",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "unknown",
    "uptake": "5.60%"
  },
  {
    "id": "243",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Connecticut",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "insurance",
    "subFilterValue": "private",
    "uptake": "7.90%"
  },
  {
    "id": "244",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Connecticut",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "insurance",
    "subFilterValue": "public",
    "uptake": "12.10%"
  },
  {
    "id": "245",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Connecticut",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "insurance",
    "subFilterValue": "no_insurance",
    "uptake": "0.00%"
  },
  {
    "id": "246",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "New York",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "preterm_birth_yes",
    "uptake": "21.50%"
  },
  {
    "id": "247",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "New York",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "lung_comorbidity",
    "uptake": "12.20%"
  },
  {
    "id": "248",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "New York",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "cardiac_comorbidity",
    "uptake": "21.70%"
  },
  {
    "id": "249",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "New York",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "anemia",
    "uptake": "11.70%"
  },
  {
    "id": "250",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "New York",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "comorbidity_yes",
    "uptake": "16.40%"
  },
  {
    "id": "251",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "New York",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "hispanic",
    "uptake": "10.40%"
  },
  {
    "id": "252",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "New York",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "white",
    "uptake": "8.30%"
  },
  {
    "id": "253",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "New York",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "black",
    "uptake": "16.10%"
  },
  {
    "id": "254",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "New York",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "multiple_other",
    "uptake": "14.90%"
  },
  {
    "id": "255",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "New York",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "unknown",
    "uptake": "5.60%"
  },
  {
    "id": "256",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "New York",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "insurance",
    "subFilterValue": "private",
    "uptake": "7.90%"
  },
  {
    "id": "257",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "New York",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "insurance",
    "subFilterValue": "public",
    "uptake": "12.10%"
  },
  {
    "id": "258",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "New York",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "insurance",
    "subFilterValue": "no_insurance",
    "uptake": "0.00%"
  },
  {
    "id": "259",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Rhode Island",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "preterm_birth_yes",
    "uptake": "21.50%"
  },
  {
    "id": "260",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Rhode Island",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "lung_comorbidity",
    "uptake": "12.20%"
  },
  {
    "id": "261",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Rhode Island",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "cardiac_comorbidity",
    "uptake": "21.70%"
  },
  {
    "id": "262",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Rhode Island",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "anemia",
    "uptake": "11.70%"
  },
  {
    "id": "263",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Rhode Island",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "comorbidity_yes",
    "uptake": "16.40%"
  },
  {
    "id": "264",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Rhode Island",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "hispanic",
    "uptake": "10.40%"
  },
  {
    "id": "265",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Rhode Island",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "white",
    "uptake": "8.30%"
  },
  {
    "id": "266",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Rhode Island",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "black",
    "uptake": "16.10%"
  },
  {
    "id": "267",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Rhode Island",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "multiple_other",
    "uptake": "14.90%"
  },
  {
    "id": "268",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Rhode Island",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "unknown",
    "uptake": "5.60%"
  },
  {
    "id": "269",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Rhode Island",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "insurance",
    "subFilterValue": "private",
    "uptake": "7.90%"
  },
  {
    "id": "270",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Rhode Island",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "insurance",
    "subFilterValue": "public",
    "uptake": "12.10%"
  },
  {
    "id": "271",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Rhode Island",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "insurance",
    "subFilterValue": "no_insurance",
    "uptake": "0.00%"
  },
  {
    "id": "272",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Connecticut",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "10.70%"
  },
  {
    "id": "273",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "New York",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "10.70%"
  },
  {
    "id": "274",
    "study": "Xu et al. (2024)",
    "healthStatus": "all_ARI",
    "country": "United States",
    "city": "Rhode Island",
    "intervention": "nirsevimab",
    "population": "under_10_months ",
    "setting": "hospital",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "10.70%"
  },
  {
    "id": "275",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "8.92%"
  },
  {
    "id": "276",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "60_to_64",
    "uptake": "4.84%"
  },
  {
    "id": "277",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "65_to_74",
    "uptake": "8.03%"
  },
  {
    "id": "278",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "75_or_more",
    "uptake": "10.29%"
  },
  {
    "id": "279",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "sex",
    "subFilterValue": "male",
    "uptake": "8.81%"
  },
  {
    "id": "280",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "sex",
    "subFilterValue": "female",
    "uptake": "9.02%"
  },
  {
    "id": "281",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "white",
    "uptake": "10.19%"
  },
  {
    "id": "282",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "hispanic",
    "uptake": "4.78%"
  },
  {
    "id": "283",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "black",
    "uptake": "4.48%"
  },
  {
    "id": "284",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "multiple_other",
    "uptake": "6.80%"
  },
  {
    "id": "285",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "unknown",
    "uptake": "3.28%"
  },
  {
    "id": "286",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "socioeconomic",
    "subFilterValue": "quartile_1",
    "uptake": "10.34%"
  },
  {
    "id": "287",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "socioeconomic",
    "subFilterValue": "quartile_2",
    "uptake": "9.00%"
  },
  {
    "id": "288",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "socioeconomic",
    "subFilterValue": "quartile_3",
    "uptake": "7.04%"
  },
  {
    "id": "289",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "socioeconomic",
    "subFilterValue": "quartile_4",
    "uptake": "5.43%"
  },
  {
    "id": "290",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "socioeconomic",
    "subFilterValue": "quartile_missing",
    "uptake": "10.12%"
  },
  {
    "id": "291",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "outcome",
    "subFilterValue": "icu",
    "uptake": "7.85%"
  },
  {
    "id": "292",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "outcome",
    "subFilterValue": "hospital_death",
    "uptake": "6.72%"
  },
  {
    "id": "293",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "comorbidities_count",
    "subFilterValue": "none",
    "uptake": "5.97%"
  },
  {
    "id": "294",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "comorbidities_count",
    "subFilterValue": "one",
    "uptake": "7.67%"
  },
  {
    "id": "295",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "comorbidities_count",
    "subFilterValue": "2_to_3",
    "uptake": "9.16%"
  },
  {
    "id": "296",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "comorbidities_count",
    "subFilterValue": "4_or _more",
    "uptake": "9.41%"
  },
  {
    "id": "297",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "lung_comorbidity",
    "uptake": "10.40%"
  },
  {
    "id": "298",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "non_lung_comorbidity",
    "uptake": "9.07%"
  },
  {
    "id": "299",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "cardiac_comorbidity",
    "uptake": "9.17%"
  },
  {
    "id": "300",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "cerebro_comorbidity",
    "uptake": "6.69%"
  },
  {
    "id": "301",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "neuro_comorbidity",
    "uptake": "8.62%"
  },
  {
    "id": "302",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "haematologic_comorbidity",
    "uptake": "9.71%"
  },
  {
    "id": "303",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "metabolic_endo_comorbidity",
    "uptake": "9.41%"
  },
  {
    "id": "304",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "renal_disease",
    "uptake": "8.72%"
  },
  {
    "id": "305",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "gastro_comorbidity",
    "uptake": "7.52%"
  },
  {
    "id": "306",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "immunosuppression",
    "uptake": "9.72%"
  },
  {
    "id": "307",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "8.37%"
  },
  {
    "id": "308",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "age_group",
    "subFilterValue": "60_to_64",
    "uptake": "3.56%"
  },
  {
    "id": "309",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "age_group",
    "subFilterValue": "65_to_74",
    "uptake": "7.70%"
  },
  {
    "id": "310",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "age_group",
    "subFilterValue": "75_or_more",
    "uptake": "10.35%"
  },
  {
    "id": "311",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "sex",
    "subFilterValue": "male",
    "uptake": "8.19%"
  },
  {
    "id": "312",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "sex",
    "subFilterValue": "female",
    "uptake": "8.51%"
  },
  {
    "id": "313",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "ethnicity",
    "subFilterValue": "white",
    "uptake": "9.96%"
  },
  {
    "id": "314",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "ethnicity",
    "subFilterValue": "hispanic",
    "uptake": "4.82%"
  },
  {
    "id": "315",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "ethnicity",
    "subFilterValue": "black",
    "uptake": "4.08%"
  },
  {
    "id": "316",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "ethnicity",
    "subFilterValue": "multiple_other",
    "uptake": "6.78%"
  },
  {
    "id": "317",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "ethnicity",
    "subFilterValue": "unknown",
    "uptake": "3.72%"
  },
  {
    "id": "318",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "socioeconomic",
    "subFilterValue": "quartile_1",
    "uptake": "10.31%"
  },
  {
    "id": "319",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "socioeconomic",
    "subFilterValue": "quartile_2",
    "uptake": "9.17%"
  },
  {
    "id": "320",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "socioeconomic",
    "subFilterValue": "quartile_3",
    "uptake": "7.04%"
  },
  {
    "id": "321",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "socioeconomic",
    "subFilterValue": "quartile_4",
    "uptake": "5.35%"
  },
  {
    "id": "322",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "socioeconomic",
    "subFilterValue": "quartile_missing",
    "uptake": "8.17%"
  },
  {
    "id": "323",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "comorbidities_count",
    "subFilterValue": "none",
    "uptake": "7.99%"
  },
  {
    "id": "324",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "comorbidities_count",
    "subFilterValue": "one",
    "uptake": "8.56%"
  },
  {
    "id": "325",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "comorbidities_count",
    "subFilterValue": "2_to_3",
    "uptake": "9.21%"
  },
  {
    "id": "326",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "comorbidities_count",
    "subFilterValue": "4_or _more",
    "uptake": "9.11%"
  },
  {
    "id": "327",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "comorbidity",
    "subFilterValue": "lung_comorbidity",
    "uptake": "9.87%"
  },
  {
    "id": "328",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "comorbidity",
    "subFilterValue": "non_lung_comorbidity",
    "uptake": "8.39%"
  },
  {
    "id": "329",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "comorbidity",
    "subFilterValue": "cardiac_comorbidity",
    "uptake": "8.50%"
  },
  {
    "id": "330",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "comorbidity",
    "subFilterValue": "cerebro_comorbidity",
    "uptake": "6.06%"
  },
  {
    "id": "331",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "comorbidity",
    "subFilterValue": "neuro_comorbidity",
    "uptake": "7.35%"
  },
  {
    "id": "332",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "comorbidity",
    "subFilterValue": "haematologic_comorbidity",
    "uptake": "11.50%"
  },
  {
    "id": "333",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "comorbidity",
    "subFilterValue": "metabolic_endo_comorbidity",
    "uptake": "8.62%"
  },
  {
    "id": "334",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "comorbidity",
    "subFilterValue": "renal_disease",
    "uptake": "8.20%"
  },
  {
    "id": "335",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "comorbidity",
    "subFilterValue": "gastro_comorbidity",
    "uptake": "9.67%"
  },
  {
    "id": "336",
    "study": "Payne (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "emergency",
    "subFilterKey": "comorbidity",
    "subFilterValue": "immunosuppression",
    "uptake": "10.30%"
  },
  {
    "id": "337",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "32.60%"
  },
  {
    "id": "338",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "maternal_age",
    "subFilterValue": "35_to_49",
    "uptake": "37.40%"
  },
  {
    "id": "339",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "maternal_age",
    "subFilterValue": "25_to_34",
    "uptake": "28.90%"
  },
  {
    "id": "340",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "maternal_age",
    "subFilterValue": "18_to_24",
    "uptake": "39.10%"
  },
  {
    "id": "341",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "ethnicity",
    "subFilterValue": "black",
    "uptake": "36.40%"
  },
  {
    "id": "342",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "ethnicity",
    "subFilterValue": "white",
    "uptake": "33.80%"
  },
  {
    "id": "343",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "ethnicity",
    "subFilterValue": "hispanic",
    "uptake": "29.30%"
  },
  {
    "id": "344",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "ethnicity",
    "subFilterValue": "multiple_other",
    "uptake": "29.90%"
  },
  {
    "id": "345",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "education",
    "subFilterValue": "maternal_edu_highest ",
    "uptake": "50.10%"
  },
  {
    "id": "346",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "education",
    "subFilterValue": "maternal_edu_college_degree ",
    "uptake": "32.70%"
  },
  {
    "id": "347",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "education",
    "subFilterValue": "maternal_edu_college ",
    "uptake": "30.00%"
  },
  {
    "id": "348",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "education",
    "subFilterValue": "maternal_edu_high_school ",
    "uptake": "28.70%"
  },
  {
    "id": "349",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "employment",
    "subFilterValue": "maternal_employ_yes",
    "uptake": "35.70%"
  },
  {
    "id": "350",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "employment",
    "subFilterValue": "maternal_employ_no",
    "uptake": "28.20%"
  },
  {
    "id": "351",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "poverty_status",
    "subFilterValue": "above_poverty",
    "uptake": "35.00%"
  },
  {
    "id": "352",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "poverty_status",
    "subFilterValue": "below_poverty",
    "uptake": "26.40%"
  },
  {
    "id": "353",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "residential_area",
    "subFilterValue": "urban",
    "uptake": "33.10%"
  },
  {
    "id": "354",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "residential_area",
    "subFilterValue": "rural",
    "uptake": "30.50%"
  },
  {
    "id": "355",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "region",
    "subFilterValue": "northeast",
    "uptake": "38.60%"
  },
  {
    "id": "356",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "region",
    "subFilterValue": "midwest",
    "uptake": "36.80%"
  },
  {
    "id": "357",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "region",
    "subFilterValue": "south",
    "uptake": "29.90%"
  },
  {
    "id": "358",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "region",
    "subFilterValue": "west",
    "uptake": "30.10%"
  },
  {
    "id": "359",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "insurance",
    "subFilterValue": "private",
    "uptake": "38.90%"
  },
  {
    "id": "360",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "insurance",
    "subFilterValue": "public",
    "uptake": "28.00%"
  },
  {
    "id": "361",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "insurance",
    "subFilterValue": "no_insurance",
    "uptake": "0.00%"
  },
  {
    "id": "362",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "provider",
    "subFilterValue": "provider_yes",
    "uptake": "56.70%"
  },
  {
    "id": "363",
    "study": "Razzaghi (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "community",
    "subFilterKey": "provider",
    "subFilterValue": "provider_no",
    "uptake": "1.90%"
  },
  {
    "id": "364",
    "study": "Reses (2023)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "9.80%"
  },
  {
    "id": "365",
    "study": "Reses (2023)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "US_HHS",
    "subFilterValue": "HHS_1",
    "uptake": "8.20%"
  },
  {
    "id": "366",
    "study": "Reses (2023)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "US_HHS",
    "subFilterValue": "HHS_2",
    "uptake": "7.10%"
  },
  {
    "id": "367",
    "study": "Reses (2023)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "US_HHS",
    "subFilterValue": "HHS_3",
    "uptake": "10.00%"
  },
  {
    "id": "368",
    "study": "Reses (2023)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "US_HHS",
    "subFilterValue": "HHS_4",
    "uptake": "5.90%"
  },
  {
    "id": "369",
    "study": "Reses (2023)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "US_HHS",
    "subFilterValue": "HHS_5",
    "uptake": "12.70%"
  },
  {
    "id": "370",
    "study": "Reses (2023)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "US_HHS",
    "subFilterValue": "HHS_6",
    "uptake": "9.20%"
  },
  {
    "id": "371",
    "study": "Reses (2023)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "US_HHS",
    "subFilterValue": "HHS_7",
    "uptake": "15.50%"
  },
  {
    "id": "372",
    "study": "Reses (2023)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "US_HHS",
    "subFilterValue": "HHS_8",
    "uptake": "24.80%"
  },
  {
    "id": "373",
    "study": "Reses (2023)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "US_HHS",
    "subFilterValue": "HHS_9",
    "uptake": "10.10%"
  },
  {
    "id": "374",
    "study": "Reses (2023)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "US_HHS",
    "subFilterValue": "HHS_10",
    "uptake": "11.70%"
  },
  {
    "id": "375",
    "study": "Reses (2023)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "SVI",
    "subFilterValue": "SVI_low",
    "uptake": "10.70%"
  },
  {
    "id": "376",
    "study": "Reses (2023)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "SVI",
    "subFilterValue": "SVI_medium",
    "uptake": "10.00%"
  },
  {
    "id": "377",
    "study": "Reses (2023)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "SVI",
    "subFilterValue": "SVI_high",
    "uptake": "8.70%"
  },
  {
    "id": "378",
    "study": "Reses (2023)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "facility_size",
    "subFilterValue": "under_59",
    "uptake": "15.30%"
  },
  {
    "id": "379",
    "study": "Reses (2023)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "facility_size",
    "subFilterValue": "59_to_94",
    "uptake": "9.30%"
  },
  {
    "id": "380",
    "study": "Reses (2023)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "facility_size",
    "subFilterValue": "95_or_more",
    "uptake": "8.00%"
  },
  {
    "id": "381",
    "study": "Reses (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "17.92%"
  },
  {
    "id": "382",
    "study": "Reses (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "US_HHS",
    "subFilterValue": "HHS_1",
    "uptake": "20.12%"
  },
  {
    "id": "383",
    "study": "Reses (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "US_HHS",
    "subFilterValue": "HHS_2",
    "uptake": "19.76%"
  },
  {
    "id": "384",
    "study": "Reses (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "US_HHS",
    "subFilterValue": "HHS_3",
    "uptake": "19.21%"
  },
  {
    "id": "385",
    "study": "Reses (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "US_HHS",
    "subFilterValue": "HHS_4",
    "uptake": "12.07%"
  },
  {
    "id": "386",
    "study": "Reses (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "US_HHS",
    "subFilterValue": "HHS_5",
    "uptake": "21.56%"
  },
  {
    "id": "387",
    "study": "Reses (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "US_HHS",
    "subFilterValue": "HHS_6",
    "uptake": "9.32%"
  },
  {
    "id": "388",
    "study": "Reses (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "US_HHS",
    "subFilterValue": "HHS_7",
    "uptake": "22.40%"
  },
  {
    "id": "389",
    "study": "Reses (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "US_HHS",
    "subFilterValue": "HHS_8",
    "uptake": "29.21%"
  },
  {
    "id": "390",
    "study": "Reses (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "US_HHS",
    "subFilterValue": "HHS_9",
    "uptake": "19.93%"
  },
  {
    "id": "391",
    "study": "Reses (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "US_HHS",
    "subFilterValue": "HHS_10",
    "uptake": "20.72%"
  },
  {
    "id": "392",
    "study": "Reses (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "SVI",
    "subFilterValue": "SVI_low",
    "uptake": "21.29%"
  },
  {
    "id": "393",
    "study": "Reses (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "SVI",
    "subFilterValue": "SVI_medium",
    "uptake": "17.48%"
  },
  {
    "id": "394",
    "study": "Reses (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "SVI",
    "subFilterValue": "SVI_high",
    "uptake": "15.31%"
  },
  {
    "id": "395",
    "study": "Reses (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "facility_size",
    "subFilterValue": "under_59",
    "uptake": "24.09%"
  },
  {
    "id": "396",
    "study": "Reses (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "facility_size",
    "subFilterValue": "59_to_94",
    "uptake": "17.69%"
  },
  {
    "id": "397",
    "study": "Reses (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "nursing_home",
    "subFilterKey": "facility_size",
    "subFilterValue": "95_or_more",
    "uptake": "15.93%"
  },
  {
    "id": "398",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "34.01%"
  },
  {
    "id": "399",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "asian",
    "uptake": "32.52%"
  },
  {
    "id": "400",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "black",
    "uptake": "22.68%"
  },
  {
    "id": "401",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "white",
    "uptake": "36.63%"
  },
  {
    "id": "402",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "other",
    "uptake": "26.21%"
  },
  {
    "id": "403",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "multiple",
    "uptake": "36.36%"
  },
  {
    "id": "404",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "hispanic",
    "uptake": "24.75%"
  },
  {
    "id": "405",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "non_hispanic",
    "uptake": "34.67%"
  },
  {
    "id": "406",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "insurance",
    "subFilterValue": "public",
    "uptake": "13.25%"
  },
  {
    "id": "407",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "insurance",
    "subFilterValue": "private",
    "uptake": "37.76%"
  },
  {
    "id": "408",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "smoking_status",
    "subFilterValue": "former_or_current_smoker",
    "uptake": "37.55%"
  },
  {
    "id": "409",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "drug_use_in_pregancy",
    "subFilterValue": "drug_use_in_pregancy",
    "uptake": "39.02%"
  },
  {
    "id": "410",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "high_BMI",
    "uptake": "32.18%"
  },
  {
    "id": "411",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "chronic_hypertension",
    "uptake": "50.00%"
  },
  {
    "id": "412",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "asthma",
    "uptake": "32.70%"
  },
  {
    "id": "413",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "SLE",
    "uptake": "22.22%"
  },
  {
    "id": "414",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "IBD",
    "uptake": "30.66%"
  },
  {
    "id": "415",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "pregestational_diabetes",
    "uptake": "18.92%"
  },
  {
    "id": "416",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "gestational_diabetes",
    "uptake": "31.61%"
  },
  {
    "id": "417",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "pregnancy_outcome",
    "subFilterValue": "IVF_pregnancy",
    "uptake": "44.49%"
  },
  {
    "id": "418",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "pregnancy_outcome",
    "subFilterValue": "nulliparous",
    "uptake": "35.58%"
  },
  {
    "id": "419",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "pregnancy_outcome",
    "subFilterValue": "cesarean_delivery",
    "uptake": "33.99%"
  },
  {
    "id": "420",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "infant_sex",
    "subFilterValue": "female",
    "uptake": "34.80%"
  },
  {
    "id": "421",
    "study": "Son (2024)",
    "healthStatus": "healthy",
    "country": "United States",
    "city": "NYC",
    "intervention": "RSV maternal vaccine",
    "population": "32_to_36_wga",
    "setting": "hospital",
    "subFilterKey": "infant_sex",
    "subFilterValue": "male",
    "uptake": "33.27%"
  },
  {
    "id": "422",
    "study": "Surie (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "total",
    "subFilterValue": "total",
    "uptake": "8.90%"
  },
  {
    "id": "423",
    "study": "Surie (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "60_to_74",
    "uptake": "6.95%"
  },
  {
    "id": "424",
    "study": "Surie (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "age_group",
    "subFilterValue": "75_or_more",
    "uptake": "11.70%"
  },
  {
    "id": "425",
    "study": "Surie (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "sex",
    "subFilterValue": "female",
    "uptake": "8.46%"
  },
  {
    "id": "426",
    "study": "Surie (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "sex",
    "subFilterValue": "male",
    "uptake": "9.36%"
  },
  {
    "id": "427",
    "study": "Surie (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "black",
    "uptake": "3.09%"
  },
  {
    "id": "428",
    "study": "Surie (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "hispanic",
    "uptake": "4.78%"
  },
  {
    "id": "429",
    "study": "Surie (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "white",
    "uptake": "11.73%"
  },
  {
    "id": "430",
    "study": "Surie (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "multiple_other",
    "uptake": "6.93%"
  },
  {
    "id": "431",
    "study": "Surie (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "ethnicity",
    "subFilterValue": "unknown",
    "uptake": "5.38%"
  },
  {
    "id": "432",
    "study": "Surie (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "comorbidity_yes",
    "uptake": "8.95%"
  },
  {
    "id": "433",
    "study": "Surie (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "comorbidity",
    "subFilterValue": "immunosuppression",
    "uptake": "11.67%"
  },
  {
    "id": "434",
    "study": "Surie (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "health_care_utilisation",
    "subFilterValue": "long_term_care",
    "uptake": "6.05%"
  },
  {
    "id": "435",
    "study": "Surie (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "health_care_utilisation",
    "subFilterValue": "outpatient_visit_year_prior",
    "uptake": "9.41%"
  },
  {
    "id": "436",
    "study": "Surie (2024)",
    "healthStatus": "rsv_ARI",
    "country": "United States",
    "city": "NA",
    "intervention": "RSV vaccine for older adults",
    "population": "60_years_or_more",
    "setting": "hospital",
    "subFilterKey": "health_care_utilisation",
    "subFilterValue": "hospitalisation_year_prior",
    "uptake": "9.02%"
  }
]